Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2008

View Archived Issues

Novel kappa opioid receptor antagonist zyklophin has therapeutic potential in drug abuse

Chiba presents novel PET ligand for in vivo alpha7 nAchR imaging at the CINP meeting

CGEN-50001 to begin proof-of-concept study in breast cancer in 2009

Jazz to raise funds through registered direct offering

Dyax enters negotiation period with Dompe for European license to DX-88 in angioedema

Pharmasset initiates USD 25.9 million registered direct offering of common stock

MediGene presents autopsy findings from patient death in clinical trial of RhuDex

Galderma receives Japanese marketing and manufacturing approval for Differin in acne

Ark receives positive feedback from EMEA regarding planned phase I trial of EG-013

Pieris selects PRS-050 as first product in pipeline based on anticalin

Anturol Gel has a promising pharmacokinetic and safety profile in healthy volunteers

BioWa and Medarex enter license agreement for Complegent technology

Alnylam and Novartis extend RNAi therapeutics collaboration agreement until October 2009

Oxford Biomedica updates DSMB recommendation to stop dosing in TRIST study of Trovax

Sigma-1 receptors, therapeutic targets in neuropsychiatric diseases

Tavocept increases survival in NSCLC study

Advisory Committee votes in favor of Doribax

Development of PTC-124 supported by Genzyme agreement and CFFT award

Adlea studied in new phase II trial in arthroscopic shoulder surgery

Novel agents for cardiovascular disorders disclosed in recent patents

MacroGenics acquires Raven Biotechnologies

New phase III trials evaluate TMC-278 in treatment-naive HIV patients

Recent patents describe new therapeutic agents for endocrine-related disorders

IND clearance for study of aromatase inhibitor MPI-676 in endometriosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.